Smith & Nephew plc: Q3 2025 Trading Update Summary
Business Context and Reporting Period
This Form 6-K filing, dated November 6, 2025, reports the Third Quarter 2025 trading results for Smith & Nephew plc, a global medical technology company. The reporting period covers the three months ended September 27, 2025. The company operates across three primary business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Key Financial Metrics
- Revenue: Q3 2025 revenue was $1,501 million, compared to $1,412 million in Q3 2024. This represents a reported growth of 6.3% and underlying growth of 5.0%.
- Profit Margin Outlook: Full-year trading profit margin is expected to expand to between 19.0% and 20.0% (2024 actual: 18.1%).
- Cash Flow: Full-year free cash flow guidance has been raised to approximately $750 million, up from a previous guidance of more than $600 million.
- Capital Allocation: A $500 million share buyback program was completed on October 7, 2025.
- Debt and Liquidity: The filing does not provide specific current debt levels or liquidity ratios, noting only strong cash generation and balance sheet health.
Material Changes vs. Prior Period
- Orthopaedics: Underlying revenue grew 4.1%. US Hip Implants showed strong growth (6.3%), offsetting a decline in US Knee Implants (-2.3%) due to portfolio rationalization. Robotics sales drove growth in Other Reconstruction (9.7% underlying).
- Sports Medicine & ENT: Underlying revenue grew 5.1%. Growth outside China was 8.9%, as Volume Based Procurement (VBP) headwinds in China began to abate. Sports Medicine Joint Repair grew 8.6% underlying.
- Advanced Wound Management: Underlying revenue grew 6.0%, led by double-digit growth (12.2%) in Advanced Wound Bioactives.
- Geography: US underlying revenue grew 5.5%. Emerging Markets underlying revenue grew 5.4%, while Other Established Markets grew 3.9% underlying.
Guidance, Outlook, and Risks
- Full Year Outlook: The company expects full-year underlying revenue growth of around 5.0% (reported around 5.7%). Trading profit margin is targeted at 19.0%–20.0%.
- Tariff Impact: Management expects a net negative impact of $15 to $20 million from tariffs in 2025, with potential compounding effects in 2026.
- Reimbursement Risks: A final CMS update on Medicare reimbursement for skin substitutes is expected to have a 25 to 50 basis point negative impact on Group trading profit margin in 2026.
- China VBP: While headwinds in Sports Medicine are easing, VBP processes for Arthroscopic Enabling Technologies and ENT are still anticipated, though expected to be smaller in impact.
- Strategy: Capital Markets Days are scheduled for December 2025 to introduce a new strategy following the conclusion of the "12-Point Plan."
Investor Verification Checklist
- Verify the sustainability of US Hip Implant growth versus the continued decline in US Knee Implants.
- Monitor the actual impact of the CMS Medicare reimbursement update on Advanced Wound Management margins in 2026.
- Assess the effectiveness of tariff mitigation strategies given the projected $15–$20 million headwind.
- Confirm the timeline and impact of upcoming Volume Based Procurement (VBP) implementations in China for ENT and Arthroscopic segments.
- Review the details of the new mid-term strategy and financial goals to be presented at the December 2025 Capital Markets Days.